Lenz & Staehelin | European Union, Switzerland | 3 Oct 2023
The Swiss government wants to encourage the use of biosimilars and generics with the aim of decreasing the costs of healthcare. Recent regulatory and…
Lenz & Staehelin | Switzerland | 26 Sep 2023
On September 22, 2023, the Swiss Federal Council announced its key guiding principles for amending the Swiss corporate sustainability reporting…
Deal
Lenz & Staehelin | Switzerland | 21 Sep 2023
On September 11, 2023, Nordic BioSite Group, a portfolio company of Adelis Equity Partners, announced that it has acquired LubioScience GmbH, the…
Lenz & Staehelin | Switzerland | 18 Sep 2023
On 14 September 2023, the SIX Regulatory Board announced that the listing rules of SDX have been amended to allow for bonds already listed on…
Lenz & Staehelin | Switzerland | 7 Sep 2023
Under the Swiss Cartel Act, a notification of planned concentrations is required if the relevant turnover thresholds pursuant to article 9(1) of the Cartel Act are met. In a recent consultation request, the Secretariat had to assess rather minor changes of a shareholder agreement between the shareholders of a company who had joint control over the company, affecting the competences of......